SCHEMBL6694739

SCHEMBL6694739

O=C(Nc1ccccc1)Nc1cc(C(=O)N2CCNCC2)ccc1N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
NPC1 O15118 2/20 0.48
TP53 P04637 2/20 0.48
MAPK14 Q16539 2/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
FAAH O00519 1/20 0.47
CCNC P24863 2/20 0.46
CDK8 P49336 2/20 0.46
PRKAB2 O43741 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701837 0.86 BCL2 (0.46) KMT2ALMNATSHRMEN1KDM4E
SCHEMBL6698106 0.86 ALDH1A1 (0.46) KMT2ALMNATSHRMEN1MAPK1
SCHEMBL6684996 0.84 KDM4E (0.53) KMT2ALMNASMN1; SMN2KDM4EMAPT
SCHEMBL29967752 0.84 KDM4E (0.53) KMT2ALMNASMN1; SMN2KDM4EMAPT
SCHEMBL6701730 0.83 KMT2A (0.48) KMT2ALMNATSHRMEN1KDM4E
SCHEMBL6700560 0.82 TP53 (0.60) KMT2ALMNATSHRMEN1SMN1; SMN2
SCHEMBL6805390 0.82 ALDH1A1 (0.49) KMT2ALMNATSHRKDM4EMAPT
SCHEMBL6696478 0.81 ALDH1A1 (0.49) KMT2ALMNATSHRL3MBTL1KDM4E
SCHEMBL6703117 0.81 MAPT (0.47) KMT2ALMNATSHRMAPK1KDM4E
SCHEMBL6697423 0.81 NPSR1 (0.49) KMT2ALMNATSHRL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 KMT2A 4455/4885LMNA 1355/4885TSHR 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.